Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Advances in the treatment of chronic myeloid leukemia.

Eiring AM, Khorashad JS, Morley K, Deininger MW.

BMC Med. 2011 Aug 26;9:99. doi: 10.1186/1741-7015-9-99. Review.

2.

Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.

Erba HP, Pham DC, Zaiden R, Vu H, Tai S.

Clin Adv Hematol Oncol. 2011 Oct;9(10):734-45. Review.

PMID:
22252576
3.

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.

Hochhaus A, Kreil S, Corbin AS, La Rosée P, Müller MC, Lahaye T, Hanfstein B, Schoch C, Cross NC, Berger U, Gschaidmeier H, Druker BJ, Hehlmann R.

Leukemia. 2002 Nov;16(11):2190-6.

5.

Targeted drugs in chronic myeloid leukemia.

Gora-Tybor J, Robak T.

Curr Med Chem. 2008;15(29):3036-51. Review.

PMID:
19075651
6.

How to choose frontline therapy for chronic myelogenous leukemia: so many drugs, not so many patients.

Shami PJ.

J Natl Compr Canc Netw. 2012 Jan;10(1):112-8; quiz 119. Review.

PMID:
22223871
7.

New strategies in controlling drug resistance in chronic myeloid leukemia.

Frame D.

Am J Health Syst Pharm. 2007 Dec 15;64(24 Suppl 15):S16-21. Review.

PMID:
18056927
8.

Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study.

Giles FJ, Rosti G, Beris P, Clark RE, le Coutre P, Mahon FX, Steegmann JL, Valent P, Saglio G.

Expert Rev Hematol. 2010 Dec;3(6):665-73. doi: 10.1586/ehm.10.61.

PMID:
21091142
9.

Flying under the radar: the new wave of BCR-ABL inhibitors.

Quintás-Cardama A, Kantarjian H, Cortes J.

Nat Rev Drug Discov. 2007 Oct;6(10):834-48. Review.

PMID:
17853901
10.

Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib.

La Rosée P, Holm-Eriksen S, Konig H, Härtel N, Ernst T, Debatin J, Mueller MC, Erben P, Binckebanck A, Wunderle L, Shou Y, Dugan M, Hehlmann R, Ottmann OG, Hochhaus A.

Haematologica. 2008 May;93(5):765-9. doi: 10.3324/haematol.12186.

11.
12.

BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices.

Kantarjian H, Cortes J.

J Natl Compr Canc Netw. 2008 Mar;6 Suppl 2:S37-42; quiz S43-S44. Review.

PMID:
18397680
13.

Once-daily dasatinib for treatment of patients with chronic myeloid leukemia.

Tyler T.

Ann Pharmacother. 2009 May;43(5):920-7. doi: 10.1345/aph.1L570. Review.

PMID:
19336654
14.

Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase.

Rosti G, Castagnetti F, Gugliotta G, Palandri F, Baccarani M.

Crit Rev Oncol Hematol. 2012 May;82(2):159-70. doi: 10.1016/j.critrevonc.2011.04.002. Review.

PMID:
21565522
15.

Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).

Walz C, Sattler M.

Crit Rev Oncol Hematol. 2006 Feb;57(2):145-64. Review.

PMID:
16213151
16.

The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.

Parker WT, Yeung DT, Yeoman AL, Altamura HK, Jamison BA, Field CR, Hodgson JG, Lustgarten S, Rivera VM, Hughes TP, Branford S.

Blood. 2016 Apr 14;127(15):1870-80. doi: 10.1182/blood-2015-09-666214.

17.

New strategies in controlling drug resistance.

Frame D.

J Manag Care Pharm. 2007 Oct;13(8 Suppl A):13-7. Review.

18.

Nilotinib: a new tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.

Jarkowski A, Sweeney RP.

Pharmacotherapy. 2008 Nov;28(11):1374-82. doi: 10.1592/phco.28.11.1374. Review.

PMID:
18956997
19.

Emerging therapies in chronic myeloid leukemia.

Gora-Tybor J.

Curr Cancer Drug Targets. 2012 Jun;12(5):458-70. Review.

PMID:
22483154
20.

New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.

O'Hare T, Eide CA, Deininger MW.

Expert Opin Investig Drugs. 2008 Jun;17(6):865-78. doi: 10.1517/13543784.17.6.865 . Review.

PMID:
18491988

Supplemental Content

Support Center